A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
525 patients around the world
Available in Argentina, United States, Colombia, Brazil, Spain
Bristol-Myers Squibb
12Research sites
525Patients around the world
This study is for people with
Multiple myeloma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Instituto Médico de la Fundación Estudios Clínicos - Rosario
Recruiting
Italia 428, Rosario - Santa Fe
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Av. Crámer 1180, CABA, Buenos Aires
Sanatorio 9 de Julio - Tucumán
Recruiting
San Juan 537, San Miguel de Tucumán, CP 4000
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Recruiting
Juan Domingo Perón 4190, Piso 1, Ciudad Autónoma de Buenos Aires, C1181ACH
Sanatorio Allende (Nueva Córdoba)
Recruiting
Hipolito Yrigoyen 384, Córdoba
Fundação Antônio Prudente - CAPEC - Centro de Apoio à Pesquisa Clínica
Recruiting
R. Prof. Antônio Prudente, 212 - Liberdade, São Paulo - SP, 01509-010
Hospital Mãe de Deus - Porto Alegre
Recruiting
R. José de Alencar, 286 - Menino Deus, Porto Alegre - RS, 90880-481, Brazil
Instituto Americas - COI
Recruiting
Americas Medical City, Av. Jorge Curi, 550 - Bloco A, Sala 347 - Barra da Tijuca, Rio de Janeiro - RJ, 22775-001
Hospital Sao Rafael
Recruiting
Av. São Rafael, 2152 - São Marcos, Salvador - BA, 41253-190